drugset / Trial / NCT04395183

5-HTP and Creatine for Depression

NCT04395183

Phase 2 Completed 43 enrolled University of Utah
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a three-armed clinical trial examining the effect of 5-hydroxytryptophan and creatine monohydrate as augmenting agents for the treatment of depression. Subjects will be randomized between 5-HTP + placebo, creatine + placebo, and 5-HTP + creatine, for 8 weeks. The ability of the interventions to affect biomarkers associated with depression will be assessed using brain phosphorus magnetic resonance spectroscopy, functional connectivity imaging, and plasma serotonin levels.

Timeline

Start
2021-03-01
Primary completion
2023-08-01
Completion
2024-03-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator 5-Hydroxytryptophan Other / unclassified 100 mg Oral
Comparator Creatine Other / unclassified 5 g Oral